Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “erlotinib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 14
Total indexed 20,548
Sponsors 1,771

Quick answer

Showing 14 pipeline programs matching "erlotinib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

14 results for “erlotinib” Back to intelligence hub

Search results

  1. BEVACIZUMAB, ERLOTINIB

    Fondazione Telethon ETS

    Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  2. RAMUCIRUMAB, ERLOTINIB

    Eli Lilly Co.

    Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  3. erlotinib

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial
  4. Erlotinib

    Solid Biosciences

    Leptomeningeal Carcinomatosis

    phase 2 small molecule terminated

    1 trial
  5. Erlotinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small-cell Lung Cancer

    phase 2 small molecule active

    1 trial
  6. Erlotinib

    Hoffmann-La Roche

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial
  7. Erlotinib

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    1 trial
  8. Erlotinib

    United Therapeutics Europe Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial
  9. Erlotinib

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial
  10. LY2875358, ERLOTINIB

    Eli Lilly Co.

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  11. eribulin mesylate + erlotinib

    Eisai Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial
  12. erlotinib [Tarceva]

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial
  13. erlotinib and bexarotene

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule completed

    1 trial
  14. erlotinib (Tarceva) and bexarotene (Targretin)

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.